Humacyte (NASDAQ:HUMA) Given New $3.00 Price Target at BTIG Research

Humacyte (NASDAQ:HUMA) had its price objective reduced by BTIG Research from $6.00 to $3.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research’s price objective suggests a potential upside of 323.73% from the stock’s previous close.

HUMA has been the subject of several other research reports. UBS Group reiterated a “buy” rating on shares of Humacyte in a research report on Monday, December 1st. D. Boral Capital restated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Tuesday, March 17th. HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Humacyte in a report on Monday, December 1st. Wall Street Zen lowered shares of Humacyte from a “hold” rating to a “sell” rating in a report on Sunday, December 21st. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Humacyte in a research note on Monday, December 29th. Seven equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $7.71.

Humacyte Trading Down 9.0%

Shares of NASDAQ HUMA traded down $0.07 during midday trading on Friday, reaching $0.71. The company had a trading volume of 4,771,957 shares, compared to its average volume of 6,601,477. The stock has a market cap of $132.59 million, a PE ratio of -3.10 and a beta of 1.89. Humacyte has a one year low of $0.70 and a one year high of $2.93. The firm’s fifty day moving average price is $1.05 and its 200-day moving average price is $1.29. The company has a quick ratio of 0.90, a current ratio of 1.62 and a debt-to-equity ratio of 2.97.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in HUMA. R Squared Ltd bought a new stake in shares of Humacyte during the 4th quarter valued at about $25,000. Atom Investors LP bought a new position in shares of Humacyte in the 4th quarter worth approximately $25,000. Truist Financial Corp bought a new stake in shares of Humacyte during the third quarter valued at approximately $28,000. Prudential Financial Inc. purchased a new stake in Humacyte in the second quarter worth $28,000. Finally, Financial Advisors Network Inc. bought a new position in Humacyte in the second quarter worth $28,000. 44.71% of the stock is currently owned by institutional investors.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.